These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7732591)

  • 41. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
    FitzGerald MG; Harkin DP; Silva-Arrieta S; MacDonald DJ; Lucchina LC; Unsal H; O'Neill E; Koh J; Finkelstein DM; Isselbacher KJ; Sober AJ; Haber DA
    Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8541-5. PubMed ID: 8710906
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation.
    Tanner FC; Boehm M; Akyürek LM; San H; Yang ZY; Tashiro J; Nabel GJ; Nabel EG
    Circulation; 2000 May; 101(17):2022-5. PubMed ID: 10790340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity.
    Khleif SN; DeGregori J; Yee CL; Otterson GA; Kaye FJ; Nevins JR; Howley PM
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4350-4. PubMed ID: 8633069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. p16 proteins from melanoma-prone families are deficient in binding to Cdk4.
    Reymond A; Brent R
    Oncogene; 1995 Sep; 11(6):1173-8. PubMed ID: 7566978
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
    Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
    Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential CDK-inhibitor gene expression in aging human diploid fibroblasts.
    Wong H; Riabowol K
    Exp Gerontol; 1996; 31(1-2):311-25. PubMed ID: 8706801
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The INK4 family of cell cycle inhibitors in cancer.
    Roussel MF
    Oncogene; 1999 Sep; 18(38):5311-7. PubMed ID: 10498883
    [No Abstract]   [Full Text] [Related]  

  • 49. Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.
    Southgate J; Proffitt J; Roberts P; Smith B; Selby P
    Br J Cancer; 1995 Nov; 72(5):1214-8. PubMed ID: 7577470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Screening for CDKN2A mutations in hereditary melanoma.
    Goldstein AM; Tucker MA
    J Natl Cancer Inst; 1997 May; 89(10):676-8. PubMed ID: 9168176
    [No Abstract]   [Full Text] [Related]  

  • 51. Viral-encoded cyclins.
    Laman H; Mann DJ; Jones NC
    Curr Opin Genet Dev; 2000 Feb; 10(1):70-4. PubMed ID: 10679390
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutations associated with familial melanoma impair p16INK4 function.
    Ranade K; Hussussian CJ; Sikorski RS; Varmus HE; Goldstein AM; Tucker MA; Serrano M; Hannon GJ; Beach D; Dracopoli NC
    Nat Genet; 1995 May; 10(1):114-6. PubMed ID: 7647780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Familial melanoma and p16--a hung jury.
    Wainwright B
    Nat Genet; 1994 Sep; 8(1):3-5. PubMed ID: 7987389
    [No Abstract]   [Full Text] [Related]  

  • 54. Current concepts in neuro-oncology: the cell cycle--a review.
    Dirks PB; Rutka JT
    Neurosurgery; 1997 May; 40(5):1000-13; discussion 1013-5. PubMed ID: 9149259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibitors of mammalian G1 cyclin-dependent kinases.
    Sherr CJ; Roberts JM
    Genes Dev; 1995 May; 9(10):1149-63. PubMed ID: 7758941
    [No Abstract]   [Full Text] [Related]  

  • 56. Molecular pathology of the cell cycle in human cancer cells.
    Bártek J; Stasková Z; Draetta G; Lukás J
    Stem Cells; 1993 May; 11 Suppl 1():51-8. PubMed ID: 8318919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New tumor suppressor may rival p53.
    Marx J
    Science; 1994 Apr; 264(5157):344-5. PubMed ID: 8153613
    [No Abstract]   [Full Text] [Related]  

  • 58. Lineage-specific regulation of cell cycle control gene expression during haematopoietic cell differentiation.
    Furukawa Y; Kikuchi J; Nakamura M; Iwase S; Yamada H; Matsuda M
    Br J Haematol; 2000 Sep; 110(3):663-73. PubMed ID: 10997979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclins and related kinases in cancer cells.
    Malumbres M
    J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
    [TBL] [Abstract][Full Text] [Related]  

  • 60. p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease.
    Omura-Minamisawa M; Diccianni MB; Chang RC; Batova A; Bridgeman LJ; Schiff J; Cohn SL; London WB; Yu AL
    Clin Cancer Res; 2001 Nov; 7(11):3481-90. PubMed ID: 11705866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.